Abstract
Among patients with Barrett's Esophagus (BE) and dysplasia, radiofrequency ablation (RFA) has emerged as the ablative modality of choice in recent years. With the increased utilization of RFA, a better quantification of the risks of the procedure is crucial.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
